Our ROR1 CAR utilized the scFv of Zilovertamab, a clinical-stage monoclonal antibody that has been shown to be safe and effective against MCL and ALL in a Phase 1⁄2 clinical trials [21]. Here, ROR1 is linked to acute lymphoblastic leukemia.